DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2024” report provides comprehensive insights about 76+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Kidney Disease Pipeline Report

• DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 76+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
• The leading companies working in the Chronic Kidney Disease market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
• Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
• April 2024:- Biocodex- Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Multiple Oral Administration of Stiripentol 1000 mg in Renal Impaired Patients and Matching Controls With Normal Renal Function. The purpose of this study is to determine whether the pharmacokinetics (PK) of stiripentol and of its relevant metabolites would be altered in subjects with renal impairment compared with normal controls in order to assess the need of dose adjustment in the renal impaired population. This study will include subjects with mild, moderate and severe renal impairment.
• April 2024:- Washington D.C. Veterans Affairs Medical Center- Effect of Empagliflozin on Podocyte Specific Proteins (Injury Markers) in African American Veterans With Albuminuric Non-Diabetic Chronic Kidney Disease. Nephropathy is a progressive complication of DKD and NDKD and substantially increases morbidity and mortality. Clinicians frequently measure proteinuria using urine protein /creatinine and urine albumin/creatinine ratios, which in several instances do not manifest substantial improvement, even after an intervention such as SGLT2i, particularly if the intervention period is is less than 6 months. There is therefore a clear need for other markers of podocyte injury in early phases of chronic kidney disease.
• Apriil 2024:- Boehringer Ingelheim- A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD). The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
• April 2024:- Chinook Therapeutics Inc.- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study). The primary objective of the study is to evaluate the effect of BION-1301 versus placebo on proteinuria in adults with IgA nephropathy. Approximately 272 patients with eGFR ≥ 30 mL/min/1.73m^2 and with biopsy-proven IgAN will be randomized to receive 600 mg Q2W BION-1301 or a matched placebo for 104 weeks. An additional exploratory cohort, not included in the primary analysis, will be comprised of approximately 20 subjects (10 subjects per arm) with biopsy-confirmed IgAN and eGFR of ≥ 20 to < 30 mL/min/1.73 m^2. The exploratory cohort will be randomized using the same schema as the primary cohort.
• April 2024:- Mineralys Therapeutics Inc.- A Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat Alone, and Lorundrostat in Combination With Dapagliflozin, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria. This is a 2-part study evaluating the efficacy and safety of lorundrostat (an aldosterone synthase inhibitor [ASI]) for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) either in combination with dapagliflozin, or alone.

 

Request a sample and discover the recent advances in Chronic Kidney Disease Treatment Drugs @ Chronic Kidney Disease Pipeline Report

 

In the Chronic Kidney Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

 

Find out more about Chronic Kidney Disease Therapeutics Assessment @ Chronic Kidney Disease Preclinical and Discovery Stage Products

 

Chronic Kidney Disease Emerging Drugs Profile

• KBP-5074: KBP Biosciences
• Ziltivekimab: Novo Nordisk
• US-APR2020: Kibow Pharma
• DM199: DiaMedica Therapeutics
• AL-01211: AceLink Therapeutics

 

Chronic Kidney Disease Pipeline Therapeutics Assessment

There are approx. 76+ Chronic Kidney Disease companies which are developing the Chronic Kidney Disease therapies. The Chronic Kidney Disease companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

 

DelveInsight’s Chronic Kidney Disease Pipeline Report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Chronic Kidney Disease Pipeline Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Learn more about the emerging Chronic Kidney Disease Pipeline Therapies @ Chronic Kidney Disease Clinical Trials Assessment

 

Scope of the Chronic Kidney Disease Pipeline Report

• Coverage- Global
• Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
• Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

 

Dive deep into rich insights for new drugs for Chronic Kidney Disease Treatment, Visit @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. KBP-5074: KBP Biosciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. DM199: DiaMedica Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AL-01211: AceLink Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SCO-116: Scohia Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Kidney Disease Key Companies
21. Chronic Kidney Disease Key Products
22. Chronic Kidney Disease- Unmet Needs
23. Chronic Kidney Disease- Market Drivers and Barriers
24. Chronic Kidney Disease- Future Perspectives and Conclusion
25. Chronic Kidney Disease Analyst Views
26. Chronic Kidney Disease Key Companies
27. Appendix

 

For further information on the Chronic Kidney Disease Pipeline therapeutics, reach out to Chronic Kidney Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/